Investigators - Basic - nelson

Peter Nelson, MD

Project 1: Immunocytoprotection in collapsing glomerulopathy

Collapsing glomerulopathy is an inflammatory proliferative podocytopathy that responds poorly to currently available therapies. To uncover new therapeutic approaches for collapsing glomerulopathy, research is ongoing to identify innate regulatory immune effectors that protect from inflammatory injury to glomerular epithelial cells.

Project 2: Renal mononuclear phagocytes in health and disease and the kidney

Mechanisms of peripheral tolerance and regulatory immunity that maintain immune homeostasis within glomerular and tubulointerstitial compartments of the kidney are poorly understood. We mapped the contiguous renal mononuclear phagocytic system and are exploring whether the innate regulatory response of renal mononuclear phgocytes attenuates inflammatory challenges to glomeruli.

Project 3: CDK/GSK-3 inhibitors as renal therapies

Small molecule CDK/GSK-3 inhibitors have emerged as promising drugs for a broad range of parenchymal renal diseases. Through various mechanisms of action on renal and non-renal cell-types, CDK/GSK-3 inhibitors suppress detrimental proliferation, apoptosis, and inflammation, and appear to promote tissue repair within the kidney. We are studying the novel CDK/GSK-3 inhibitors as potential therapeutic agents for glomerular diseases.

Project 4: The Nephrotic Syndrome Study Network (NEPTUNE)

Bedside-to-bench-to-bedside translational research in nephrotic renal diseases has been hampered by the lack of a collaborative research network that leverages resources to understand and treat these diseases. Under the umbrella of the Kidney Research Institute, the University of Washington Medical Center and affiliates, Seattle Children's Hospital and Providence Sacred Heart Hospital, join 18 other academic medical centers in the US and Canada to prospectively study patients newly diagnosed with minimal change disease, focal segmental glomerulosclerosis, or membranous nephropathy. High fidelity clinical, pathologic, and molecular phenotypes assembled from these patients will be integrated to identify targetable disease pathways and new biomarkers of progression and remission. Interventional trials for these diseases are also a major focus of NEPTUNE.

Current Funding

R01 DK083375 (Nelson, PI)
Immunocytoprotection in collapsing glomerulopathy

U54 DK083912 (Clinical Center: Nelson, PI)
The Nephrotic Syndrome Study Network (NEPTUNE)

Sponsored Research Grant (Nelson, PI)
Genzyme Corporation
Pre-clincal testing of Genz-123 in a murine model of collapsing glomerulopathy

Past Funding

R01 DK083375-S1 (Nelson, PI) NIH/NIDDK
Re-entry supplement to DK083375

R03 DK079498 (Nelson, PI)
TNF-α: an immunologic precipitant of collapsing glomerulopathy

K08 DK065498 (Nelson, PI)
Immune mechanisms in collapsing glomerulopathy

Saperstein Grant (Nelson, PI)
Michael Saperstein Scholarship Program
Dendritic cells in proteinuria

Sponsored Research Grant (Nelson, PI)
Cyclacel, Ltd
Pre-clinical optimization of CYC202 in a murine model of collapsing glomerulopathy

Sponsored Research Grant (Nelson, PI)
Cyclacel, Ltd
Pre-clinical testing of CYC202 in a murine model of collapsing glomerulopathy

Research Fellowship Grant (Nelson, PI)
National Kidney Foundation
Targeting cell-cycle progression in HIV-associated collapsing glomerulopathy

Current Research Members

Prasanthi Karna, PhD: research scientist

Laura Curtin: research coordinator


PubMed provides a list of Dr. Nelson's research publications